Clinical trials: Mecamylamine
Autistic Disorder, Pervasive Developmental Disorder
Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders
The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.
- Trial name
- NCT00773812
- Testing
- mecamylamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Healthy Volunteers, Patients
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
The purpose of this study is to compare the absorption and distribution of a single oral dose of TC-5214 in subjects with renal impairment and with subjects with normal renal function.
- Conditions
- Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
- Trial name
- NCT01240967
- Testing
- TC-5214
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alcoholism
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients.
- Trial name
- NCT00342563
- Testing
- mecamylamine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Yale University
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Healthy Subjects
Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214
(Food versus no food) crossover study to measure the effects of food on pharmacokinetics of TC-5214 (S-Mecamylamine) in healthy Subjects.
- Trial name
- TC-5214 (NCT01458899)
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Age-Related Macular Degeneration
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab.
- Trial name
- NCT00607750
- Testing
- ATG003 (mecamylamine)
- Volunteers
- 60 people
- Sponsor
- CoMentis
Major Depressive Disorder
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have an inadequate response (partial or non-responder) will be randomized to receive either mecamylamine (5-10mg) or placebo added to their…
- Trial name
- NCT00593879
- Testing
- Mecamylamine
- Volunteers
- 450 people
- Sponsor
- Targacept Inc.
Healthy
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
To investigate the safety and tolerability of TC-5214 following oral administration of single and multiple ascending doses compared to placebo.
- Trial name
- NCT01145768
- Testing
- TC-5214
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01157078
- Testing
- TC-5214
- Where
- 51 sites in United States, India
- Volunteers
- 319 people
- Sponsor
- AstraZeneca
Healthy
To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects
The purpose of this study is to assess safety, tolerability and pharmacokinetics after a single and repeated oral doses of TC-5214 (S-mecamylamine) in healthy male Japanese subjects.
- Trial name
- NCT01175564
- Testing
- TC-5214
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Smoking
Combinations of Pharmacologic Smoking Cessation Treatments
The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.
- Trial name
- NCT00018187
- Testing
- Bupropion, Mecamylamine, Nicotine Patch
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Alcohol Dependence, Depression
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence.
- Trial name
- NCT00563797
- Testing
- Mecamylamine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Nicotine Dependence
Nicotinic Modulation of the Default Network of Resting Brain Function
Background: A brain circuit called the default network is the brain circuit that is active when the brain is at rest; that is, when individuals are not concentrating on specific tasks.
- Trial name
- NCT01240616
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Spinal Cord Injuries
Mecamylamine for Autonomic Dysreflexia Prophylaxis
This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI).
- Trial name
- NCT03914677
- Testing
- Mecamylamine Oral Tablet
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wayne State University
Magnetic Resonance Imaging, Cognition
Nicotinic Modulation of the Default Network
Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed…
- Conditions
- Magnetic Resonance Imaging, Cognition, Nicotine, Mecamylamine
- Trial name
- NCT01223404
- Testing
- Nicotine, Mecamylamine
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore